Slightly recovered, digestive system drug market increased by 2.17% year on year

[market analysis of pharmaceutical Station] digestive system drugs include antacids, drugs for inhibiting gastric acid secretion, gastrointestinal stimulants, antiemetics, antidiarrheal drugs, drugs for treating liver and gall diseases, etc According to the statistics of relevant data, in 2018, the sales volume of digestive system drugs in hospitals in key cities in China was 18.727 billion yuan, with a year-on-year growth rate of 2.17%, slightly higher than the previous year Among the digestive system drugs, proton pump inhibitors, liver diseases drugs and antiemetics accounted for 37.54%, 22.29% and 11.26% of the total sales in the domestic market respectively, ranking the top three treatment categories In contrast, proton pump inhibitors, laxatives and digestive AIDS rank higher in the global market In addition, the growth potential of gastrointestinal antispasmodic and anticholinergic drugs is great The growth rate of digestive aid, cathartic, cholepathy medicine and mucosal protective agent is more than 10%, which is consistent with the whole field From the perspective of competition pattern, the top three enterprises, AstraZeneca (AstraZeneca), Zhengda Tianqing pharmaceutical and Jiangsu aosaikang pharmaceutical, respectively, accounted for 6.65% and 5.34% of the domestic key city hospital market shares But on the whole, the advantages of leading enterprises are not obvious At present, only montmorillonite powder, polyethylene glycol 4000 powder, procapride Succinate Tablets, ranitidine hydrochloride capsules and other products have passed the consistency evaluation of generic drugs for digestive system drugs In addition, in the first three quarters of 2018, among the types of digestive system chemicals in public hospitals in key cities, the use frequency of proton pump inhibitors is relatively high Proton pump inhibitors are an important class of drugs to inhibit gastric acid secretion after H2 receptor blockers, and also a class of drugs with strong inhibition of gastric acid secretion at present Among the top 10 chemical products, the common clinical products such as esmoloprazole, lansoprazole, omeprazole and pantoprazole are listed Among the top 10 chemical brands, isoglycyrrhizic acid magnesium injection of Zhengda Tianqing Pharmaceutical Group, esmeralazole sodium for injection of AstraZeneca and Lansoprazole for injection of Roxin Pharmaceutical Group lead the digestive system drug market Taking esomeprazole sodium for injection and esomeprazole magnesium enteric coated tablets as examples, the drug is a proton pump inhibitor and the main product of AstraZeneca According to statistics, at present, there are as many as 13 manufacturers that have approved the production of esomeprazole sodium for injection And only AstraZeneca has the approval of esomeprazole magnesium intestinal antler tablets In addition, in the traditional Chinese medicine for digestive system, hepatitis, stomach (gastritis, ulcer), hemorrhoids and constipation are the main drug types In the first three quarters of 2018, the sales volume of the top five types of Chinese patent medicine for digestive system in public hospitals in key cities exceeded 100 million yuan, and the sales volume of hepatitis medicine and stomach medicine (gastritis and ulcer) exceeded 700 million yuan and 400 million yuan respectively With the change of living habits, digestive system diseases have become a kind of common diseases In addition, the digestive system contains many organs, the causes of the disease are complex, and clinical diseases are common, so the market demand is still increasing According to some reports, colorectal cancer, liver cancer, esophageal cancer and gastric cancer are common cancers of digestive system in China People need to pay more attention to diet habits, digestive system diseases and drug safety in daily life.